Peru suspends China's Sinopharm COVID-19 vaccine trial

▴ Peru suspends China's Sinopharm COVID-19 vaccine trial
Peru suspended trials for China's Sinopharm COVID-19 vaccine due to a "serious adverse event" that occurred with one of the volunteers for the study, the Peruvian government said in a statement on Saturday.

German Malaga, chief researcher at the local Cayetano Heredia University, which is involved with the study, said one volunteer had experienced decreased strength in his legs, among other symptoms.

Malaga also said he was hopeful the suspension would lifted and the trial resume in a short period of time.

The health ministry said the event is "under investigation to determine if it is related to the vaccine or if there is another explanation."

Sinopharm Group Co Ltd, which is conducting its trials in Peru with some 12,000 volunteers, was about to complete the first stage of the trials in the next few days. Some 36,544 people have died so far in Peru from the coronavirus pandemic.

Back at home India steadily following the trend set over the past few weeks. Country's active caseload has fallen to 3.62% of the total active cases.

India has reported more daily recoveries than the daily new cases during the past 48 hours. The trend of more daily recoveries than the daily cases has led to a continuous contraction of India’s Active Caseload which presently stands at 3,56,546 yesterday.

While 30,254 persons in were found to be COVID positive in the country in the past 24 hours, 33,136 new recoveries were registered during the same period. This has led to a net decline of 3,273 cases from the total Active Caseload in the last 24 hours.

Tags : #Peru #LatestCOVIDNews14thDec #LatestCOVIDVaccineNews14thDec #Sinopharm #China #India #ActiveCaseload #IndiaFightsCorona #Unite2FightCorona

About the Author

Team Medicircle

Related Stories

Loading Please wait...